External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

<ul><li>Consolidated occupancies exhibited a decline of 770 bps/10 bps YoY/QoQ, reaching 49.7%. </li><li>ARPOB increased by 22.9% YoY but reported a sequential decline of 0.5% to Rs 38,263 during Q2FY25, driven by a reduction in ALOs to 3.67, a change in case mix, revised prices, and TPA negotiations. </li><li>EBITDA margins stood at 28.1%, up 88 bps/200 bps YoY/QoQ, supported by lower employee expenses. The reported PAT was Rs 121 Cr, increasing by 19.4% YoY due to improved operating profitability. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Consolidated occupancies exhibited a decline of 770 bps/10 bps YoY/QoQ, reaching 49.7%. ARPOB increased by 22.9% YoY but reported a sequential decline of 0.5% to Rs 38,263 during Q2FY25, driven by a reduction in ALOs to 3.67, a change in case mix, revised prices, and TPA negotiations. EBITDA margins stood at 28.1%, up 88 bps/200 bps YoY/QoQ, supported by lower employee expenses. The reported PAT was Rs 121 Cr, increasing by 19.4% YoY due to improved operating profitability. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Lower Occupancies

<ul><li>Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.</li><li>This trend has been evident among key players such as KIMS, Apollo, and Aster DM over the last six quarters.</li><li>Q1FY25 occupancies highlighted softness in KIMS' matured hospitals, which constitute 50% of its revenue from Telangana and AP. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.This trend has been evident among key players such as KIMS, Apollo, and Aster DM over the last six quarters.Q1FY25 occupancies highlighted softness in KIMS' matured hospitals, which constitute 50% of its revenue from Telangana and AP. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Lower Occupancies; Higher ARPOB

External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.</li><li>Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.</li><li>The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences - Growth to Improve

<ul><li>Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.</li><li>It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.</li><li>The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

Thematic (Sector/Industry)

<ul><li>We anticipate that the pharmaceutical companies within our coverage will collectively demonstrate revenue growth of 8.5% YoY and 3.1% QoQ, along with EBITDA growth of 10.5% YoY and 3.8% QoQ.</li><li>Moreover, adjusted PAT is expected to grow by 14% YoY and 1% QoQ.</li><li>This growth will likely be driven by domestic formulations and niche launches in the US market. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We anticipate that the pharmaceutical companies within our coverage will collectively demonstrate revenue growth of 8.5% YoY and 3.1% QoQ, along with EBITDA growth of 10.5% YoY and 3.8% QoQ.Moreover, adjusted PAT is expected to grow by 14% YoY and 1% QoQ.This growth will likely be driven by domestic formulations and niche launches in the US market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Krishna Institute of Medical Sciences Limited provides hospital services. The Hospital offers medical and surgical, renal and cardiac sciences, oncology, orthopaedics, organ transplantation, neurosciences, and other health care services. Krishna Institute of Medical Sciences serves patients in India.

Krishna Institute of Medical Sciences (KIMS IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

Krishna Institute of Medical Sciences Ltd - Lower Occupancies

ARPOB increased by 22.9% YoY but reported a sequential decline of 0.5% to Rs 38,263 during Q2FY25, driven by a reduction in ALOs to 3.67, a change...

Axis Direct

Krishna Institute of Medical Sciences Ltd - Lower Occupancies; Higher ARPOB

Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.

Axis Direct

Krishna Institute of Medical Sciences - Growth to Improve

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences. We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical...

Prabhudas Lilladhar

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

Additionally, there was a 3.2%/-1.3% YoY/QoQ rise in ARPOB to Rs 30,741 during Q3FY24 which was below the industry levels.

Axis Direct

Q2FY25 Earnings Preview - Pharma

We anticipate that the pharmaceutical companies within our coverage will collectively demonstrate revenue growth of 8.5% YoY and 3.1% QoQ, along...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)